Previsioni di mercato dei prodotti terapeutici per le malattie infettive del Sud e Centro America fino al 2030 - Analisi regionale - per classe di farmaci (antivirali, antibatterici, antifungini e altri), indicazione (HIV, epatite, tubercolosi, influenza, HPV e altri) , via di somministrazione (orale, parenterale, topica e altri) e canale di distribuzione (farmacie ospedaliere, farmacie al dettaglio e altri)
Le crescenti opportunità nei paesi in via di sviluppo alimentano il mercato terapeutico delle malattie infettive in Sud e Centro America.
Si prevede che la crescente incidenza delle malattie infettive aumentare le vendite di farmaci terapeutici per malattie infettive nei paesi in via di sviluppo. Inoltre, gli elevati investimenti nella ricerca sanitaria e nelle scienze della vita nei paesi emergenti svolgono un ruolo chiave nella promozione delle ultime tecnologie nei paesi in via di sviluppo, il che, a sua volta, sostiene la tendenza verso la diagnosi e il trattamento delle malattie infettive. L’UNAIDS, ad esempio, chiede un investimento di 29 miliardi di dollari entro il 2025 per soddisfare le esigenze dei paesi a basso e medio reddito nella risposta all’AIDS. Pertanto, si prevede che i produttori cruciali di prodotti terapeutici per malattie infettive nei mercati emergenti di prodotti terapeutici per malattie infettive in Brasile saranno testimoni di opportunità redditizie in futuro. Ciò è dovuto all’elevata prevalenza di malattie infettive come l’epatite, l’HAI, l’HIV e l’influenza; una vasta popolazione di pazienti; un aumento del reddito disponibile della popolazione; miglioramento delle infrastrutture sanitarie; e la crescita del turismo medico in questi paesi.
Panoramica del mercato dei prodotti terapeutici per le malattie infettive nell\'America meridionale e centrale
Il mercato dei prodotti terapeutici per le malattie infettive nell\'America meridionale e centrale è suddiviso in Brasile, Argentina e nel resto dell\'America meridionale e centrale. Si prevede che il mercato delle terapie per le malattie infettive nell’America meridionale e centrale crescerà a causa della maggiore prevalenza di malattie infettive, dell’aumento delle attività di ricerca e dell’aumento della spesa sanitaria da parte dei paesi regionali. Il Brasile ha compiuto enormi progressi nel settore sanitario grazie all’espansione della spesa sanitaria. Secondo l’International Trade Administration, il Brasile spende circa il 9,1% del suo PIL per l’assistenza sanitaria ed è il principale mercato sanitario in America Latina. Si stima che il mercato delle terapie per le malattie infettive in Brasile sia in forte espansione a causa della crescente prevalenza di malattie infettive.
Le malattie infettive sono ancora importanti cause di morte in Brasile. Da un’indagine è emerso che tra gli uomini e i bambini sotto i 5 anni è stato osservato un elevato numero di malattie infettive, dovute principalmente all’HIV/AIDS. Secondo i dati forniti dal Programma congiunto delle Nazioni Unite sull’HIV/AIDS (UNAIDS), nel 2022, circa 990.000 persone vivevano con l’HIV e l’AIDS in Brasile. Pertanto, a causa dei fattori di cui sopra, si prevede che il mercato delle terapie per le malattie infettive in Brasile crescerà durante il periodo di previsione.
Entrate e previsioni del mercato dei prodotti terapeutici per le malattie infettive dell\'America meridionale e centrale fino al 2030 (milioni di dollari)
Segmentazione del mercato dei prodotti terapeutici per le malattie infettive dell\'America meridionale e centrale
America del Sud e Centrale Il mercato delle terapie per le malattie infettive è classificato in classe di farmaco, indicazione, via di somministrazione, canale di distribuzione e paese.
In base alla classe di farmaci, il mercato delle terapie per le malattie infettive del Sud e Centro America è segmentato in antivirali, antibatterici, antifungini e altri. Il segmento antivirale ha detenuto la quota di mercato maggiore nel 2022.
In termini di indicazione, il mercato delle terapie per le malattie infettive dell\'America meridionale e centrale è segmentato in HIV, epatite, tubercolosi, influenza, HPV e altri. L\'HIV ha detenuto la quota di mercato maggiore nel 2022.
In base alla via di somministrazione, il mercato delle terapie per le malattie infettive dell\'America meridionale e centrale è segmentato in orale, parenterale, topico e altri. Il segmento orale ha detenuto la quota di mercato maggiore nel 2022.
In termini di canale di distribuzione, il mercato delle terapie per le malattie infettive del Sud e Centro America è segmentato in farmacie ospedaliere, farmacie al dettaglio e altri. Le farmacie ospedaliere detenevano la quota di mercato maggiore nel 2022.
Per paese, il mercato delle terapie per le malattie infettive dell\'America meridionale e centrale è segmentato in Brasile, Argentina e il resto dell\'America meridionale e centrale. Il Brasile ha dominato la quota di mercato delle terapie per le malattie infettive dell\'America centrale e meridionale nel 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc e Pfizer Inc sono alcune delle aziende leader che operano nel mercato terapeutico delle malattie infettive del Sud e Centro America.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - South & Central America Market Analysis
5.1 South & Central America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. South & Central America Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Infectious Disease Therapeutics Market - Country Analysis
10.1 South & Central America Infectious Disease Therapeutics Market
10.1.1 South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Brazil: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.2.2 Brazil: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.2.3 Brazil: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.2.4 Brazil: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.3 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.4 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Argentina: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.4.2 Argentina: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.4.3 Argentina: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.4.4 Argentina: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.5 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.6 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.6.2 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.6.3 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.6.4 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bayer AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AbbVie Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. South & Central America Infectious Disease Therapeutics Market Segmentation
Table 2. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Country
Table 7. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 20. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. South & Central America Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. South & Central America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. South & Central America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. South & Central America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. South & Central America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. South & Central America Infectious Disease Therapeutics Market, By Key Country - Revenue (2022) (US$ Million)
Figure 26. South & Central America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc
7. Merck & Co Inc
8. Pfizer Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South & Central America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.